Boston Scientific Corporation
BSXFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
16,747
Cost of Revenue
6,480
Gross Profit
10,267
Gross Margin
61.3%
Operating Income
2,635
Operating Margin
15.7%
Net Income
1,854
Net Margin
11.1%
EPS (Basic)
$1.26
EPS (Diluted)
$1.25
EBITDA
3,938
EBITDA Margin
23.5%
2023
12/31/2023
Revenue
14,240
Cost of Revenue
5,409
Gross Profit
8,831
Gross Margin
62.0%
Operating Income
2,181
Operating Margin
15.3%
Net Income
1,593
Net Margin
11.2%
EPS (Basic)
$1.08
EPS (Diluted)
$1.07
EBITDA
3,453
EBITDA Margin
24.2%
2022
12/31/2022
Revenue
12,682
Cost of Revenue
4,968
Gross Profit
7,714
Gross Margin
60.8%
Operating Income
1,824
Operating Margin
14.4%
Net Income
698
Net Margin
5.5%
EPS (Basic)
$0.45
EPS (Diluted)
$0.45
EBITDA
2,741
EBITDA Margin
21.6%
2021
12/31/2021
Revenue
11,888
Cost of Revenue
4,427
Gross Profit
7,461
Gross Margin
62.8%
Operating Income
1,922
Operating Margin
16.2%
Net Income
1,040
Net Margin
8.7%
EPS (Basic)
$0.69
EPS (Diluted)
$0.69
EBITDA
2,518
EBITDA Margin
21.2%
2020
12/31/2020
Revenue
9,913
Cost of Revenue
4,337
Gross Profit
5,576
Gross Margin
56.2%
Operating Income
601
Operating Margin
6.1%
Net Income
-82
Net Margin
-0.8%
EPS (Basic)
$-0.08
EPS (Diluted)
$-0.08
EBITDA
1,511
EBITDA Margin
15.2%